Navigation Links
Cambrex Receives Notice Regarding NYSE Listing
Date:4/14/2009

ncluding, without limitation, statements regarding expected performance, especially expectations with respect to sales, research and development expenditures, earnings per share, capital expenditures, acquisitions, divestitures, collaborations, or other expansion opportunities. These statements may be identified by the fact that they use words such as "expects," "anticipates," "intends," "estimates," "believes" or similar expressions in connection with any discussion of future financial and operating performance. Any forward-looking statements are qualified in their entirety by reference to the factors discussed throughout the Company's public filings. Any forward-looking statements contained herein are based on current plans and expectations and involve risks and uncertainties that could cause actual outcomes and results to differ materially from current expectations including, but not limited to, global economic trends, pharmaceutical outsourcing trends, competitive pricing or product developments, government legislation and regulations (particularly environmental issues), tax rate, interest rate, technology, manufacturing and legal issues, including the outcome of outstanding litigation disclosed in the Company's public filings, the Company's ability to satisfy the continued listing standards of the New York Stock Exchange, changes in foreign exchange rates, uncollectible receivables, loss on disposition of assets, cancellation or delays in renewal of contracts, lack of suitable raw materials or packaging materials, and the Company's ability to receive regulatory approvals for its products and other factors described under the caption "Risk Factors That May Affect Future Results" in our annual report on Form 10-K for the year ended December 31, 2008. Any forward-looking statement speaks only as of the date on which it is made, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, fu
'/>"/>
SOURCE Cambrex Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cambrex Presentation at the JPMorgan Healthcare Conference to be Webcast
2. Cambrex to Announce Fourth Quarter and Full Year 2007 Financial Results on February 14, 2008
3. Cambrex Appoints Steven M. Klosk as President and CEO
4. Cambrex Reports Third Quarter 2008 Results
5. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
6. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
7. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
8. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
9. IsoTis Receives FDA Clearance for Accell Family of Products
10. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
11. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... UK (PRWEB) January 13, 2014 Bob ... with more than 20 years in the industry, has ... photonics . Hainsey will serve as the society’s Science ... Dr. Hainsey join SPIE as our Technology Strategist, further ...
(Date:1/14/2014)... During the 1600’s through the 1800’s doctors contributed ... In this time period, doctors did not know that they ... the death of vulnerable patients. In the same way, medical ... be unwittingly transmitting herpes viruses to their patients. The CBCD ...
(Date:1/14/2014)... 14, 2014 BioMedomics, Inc. , a ... diagnostic platforms and novel disease specific POC tests, announced today ... netting a total of $690,000. The investment is from private ... company. This group of private investors has significant successful experience ...
(Date:1/14/2014)... Panama (PRWEB) January 14, 2014 ... received the county’s first clinical trial approval for ... cord-derived mesenchymal stem cells (MSC) from the Comité ... Board (IRB). , Rheumatoid Arthritis (RA) is an ...
Breaking Biology Technology:Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3BioMedomics, Inc. Closes $690K Round of Financing 2Panama’s First Umbilical Cord Stem Cell Clinical Trial for Rheumatoid Arthritis Approved by Comité Nacional de Bioética de la Investigación Institutional Review Board 2Panama’s First Umbilical Cord Stem Cell Clinical Trial for Rheumatoid Arthritis Approved by Comité Nacional de Bioética de la Investigación Institutional Review Board 3
... Sept. 8 /PRNewswire-FirstCall/,-- Concuity, a healthcare division ... a leading,provider of contract management and revenue ... today announced that Valley Baptist Health,System has ... more,accurately calculate payments from managed care and ...
... (Nasdaq: CTICD ; and MTA: CTIC) announced ... Listing Qualifications Staff of The NASDAQ Stock,Market LLC ... with the,$50,000,000 minimum market value of listed securities ... the Company does not,comply with NASDAQ Marketplace Rule ...
... Just as test pilots push planes to explore ... Standards and Technology (NIST) are probing the newest ... the nanoscale. Better nanoscale measurements are critical for ... and nanomanufacturing industries. , This new microscope technology ...
Cached Biology Technology:Valley Baptist Health System Selects Concuity's ClearContracts to More Accurately Calculate Payments from Managed Care and Government Payers 2Valley Baptist Health System Selects Concuity's ClearContracts to More Accurately Calculate Payments from Managed Care and Government Payers 3Valley Baptist Health System Selects Concuity's ClearContracts to More Accurately Calculate Payments from Managed Care and Government Payers 4CTI Receives NASDAQ Letter 2CTI Receives NASDAQ Letter 3NIST studies how new helium ion microscope measures up 2
(Date:7/9/2014)... Sexual selection refers to species, selection for traits that ... of natural selection enhances opportunities to mate, the tail ... at the University of California, Riverside have now found ... a placenta are linked. Describing the life histories ... family Poeciliidae, the researchers found that species with placentas ...
(Date:7/9/2014)... (TCGA) Research Network have identified novel mutations in ... most common subtype of lung cancer. Knowledge of ... possible therapeutic targets for this disease and potentially ... mutations because many potent cancer drugs that target ... funded and managed by the National Cancer Institute ...
(Date:7/9/2014)... With grilling season upon us, many backyard cooks are ... fatty hot dogs. But low fat can sometimes mean ... addressing the texture problem in low-fat wieners that are ... study was published in ACS, Journal of Agricultural ... colleagues note that hot-dog consumers have come to expect ...
Breaking Biology News(10 mins):Biologists link sexual selection and placenta formation 2Biologists link sexual selection and placenta formation 3Biologists link sexual selection and placenta formation 4Study identifies novel genomic changes in the most common type of lung cancer 2Study identifies novel genomic changes in the most common type of lung cancer 3
... those hoping to start or extend a family should ... Current clinical guidelines already recommend that women who are ... based on the knowledge that cholesterol is essential for ... the risk of congenital anomalies in children of pregnant ...
... pollution are decreasing the growth of trees in the northern ... in Global Change Biology . Tree growth, measured ... and this is set to increase to a 17% reduction ... four times greater now than prior to the Industrial Revolution ...
... momentum of,September,s impressive showing at the ePassports EAC Conformity ... advances its role as the,world,s ePassport leader by being ... advanced second-generation ePassports based on the,Extended Access Control (EAC) ... ePassports represent the beginning of an evolution that,will improve ...
Cached Biology News:Statin warning for pregnant women 2Surface-level ozone pollution set to reduce tree growth 10 percent by 2100 2The Finnish Population Register Centre to Deploy Entrust EAC ePassport CA Solution 2The Finnish Population Register Centre to Deploy Entrust EAC ePassport CA Solution 3The Finnish Population Register Centre to Deploy Entrust EAC ePassport CA Solution 4
... SYBR Green II RNA gel stain ... has bright fluorescence when bound to RNA and ... use with either formaldehyde/agarose or polyacrylamide gels using ... stains 50 minigels. A 1 mL unit size ...
Sirtuin 7 (SIRT7) Rabbit anti-Human Polyclonal Antibody Immunogen: Synthetic peptide - KLH conjugated Family: Other Recommended Storage: Long term: -20C; Short term: +4C...
... RSH-4000 is the only microplate sealer with ... long walkaway times with a variety of ... Fully automated with integrated stacker and 240-plate ... EX for use in small workcells , ...
... Reagents for the differentiation of mouse embryonic ... bodies exist in the midbrain, where they ... the ventral tegmental area, and the retrorubral ... to extensive forebrain dopamine innervation ( e.g.projections ...
Biology Products: